The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disease kinetics and practice patterns in = 4-year long-term beneficiaries of immune checkpoint inhibitors for advanced non–small cell lung cancer.
 
Masahiro Torasawa
Speakers' Bureau - Amgen; Amgen; AstraZeneca; AstraZeneca; Chugai Pharma; Eisai; MSD K.K; Taiho Pharmaceutical; Takeda
 
Yoshihiro Masui
No Relationships to Disclose
 
Keita Miura
Honoraria - AstraZeneca; Chugai Pharma; MSD; Regeneron
 
Shunichi Kataoka
Honoraria - Chugai Pharma
 
Masayuki Shirasawa
No Relationships to Disclose
 
Yoshiro Nakahara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - JSPS KAKENHI
 
Junko Baba
No Relationships to Disclose
 
Hidenobu Ishii
Honoraria - AMCO; AstraZeneca Japan; Chugai Pharma; Sysmex
Speakers' Bureau - AMCO; AstraZeneca Japan; Chugai Pharma; Sysmex
 
Maiko Asai
Employment - Novartis (I)
Honoraria - Chugai Pharma
 
Tomoki Aiba
Honoraria - Amgen; AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; Takeda
 
Hiroshi Wakui
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyouwa Kirin; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Shunichi Sugawara
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novocure (Inst); Parexel International (Inst); PharmaMar (Inst); PPD-SNBL (Inst); Taiho Pharmaceutical (Inst)
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyowa Kirin International; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Hisamitsu Pharmaceutical; Janssen; Lilly; Merck KGaA; MSD; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Delta-Fly Pharma (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Katsuhiko Naoki
Honoraria - asahi kasei; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Insmed; Janssen; Kyorin; Lilly; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Ltd
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhisa Takahashi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Insmed GK.; Janssen; Kyorin; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Sawai Pharmaceutical Co; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - Chugai Pharma; MSD K. K.; Ono Pharmaceutical
 
Hirotsugu Kenmotsu
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Guardant Health; Janssen; Janssen; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Loxo (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Natera; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Natera (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)